Intellectual Property & Science is now known as Clarivate Analytics

Intellectual Property & Science is now known as Clarivate Analytics

...and is no longer part of Thomson Reuters. You can still explore their products on this page.


The daily biopharmaceutical news source


Every customer we serve needs a trusted source of industry news and BioWorld Today is the news source of record for the biopharma industry. BioWorld’s readers are executives and partners in the C-suite. They are deal makers who control budgets and make decisions. A BioWorld subscription can be the perfect starting point, a gateway to discussions about additional solutions, or the logical add-on to an existing portfolio of business.

BioWorld is timely and news-driven but, unlike many competitors, provides insight and perspective, looking at the story behind the story. We interview the principals at companies that are making the news but add commentary from analysts and others that puts the new developments into context. Each daily update provides actionable intelligence on the business, clinical, scientific and regulatory news affecting the biopharma industry.


  • Daily news coverage includes: Therapeutic product development from early to late stage
  • Strategic alliances, mergers and acquisitions
  • Corporate financings, both public and private
  • Biotech company advancements and setbacks
  • Scientific Milestones
  • Global regulatory updates
  • Profiles of new and mature biotech and specialty pharmaceutical firms
  • Big pharma's growing involvement in biotech


  • Delivers actionable intelligence on the biotech science that drives the industry
  • Instant access to a wealth of biotechnology market intelligence from every biotech hotspot around the globe
  • Insightful, up-to-the-minute news coverage
  • Important, well-organized data, expert analysis